HEALTH● LOW2h ago · Sep 13, 2026, 5:23 PM
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
Seeking Alpha Tech · global
A clinical trial shows that Summit's drug, ivonescimab, reduced the risk of death by 27% compared to Keytruda in lung cancer patients. This represents a significant finding in oncology research.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH2h agoWhat became of Ardi Rizal, the child who became famous for smoking 40 cigarettes a dayClarínHEALTH2h agoScholar Rock jumps 12% after FDA approves isembyld for spinal muscular atrophySeeking Alpha TechHEALTH3h agoKochi Corporation to roll out nutrient kits under TB eradication driveThe HinduHEALTH4h agoGetting your hands dirty improves health in a few weeksBBC Afrique